In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.

@article{Salcedo2009InVA,
  title={In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.},
  author={Carolina Salcedo and S Davalillo and J Cabellos and Candela Lagunas and Dolors Balsa and Sof{\'i}a P{\'e}rez-Del-Pulgar and Mario Ballarin and Ag Fern{\'a}ndez},
  journal={British journal of pharmacology},
  year={2009},
  volume={156 5},
  pages={807-17}
}
BACKGROUND AND PURPOSE Highly selective M(3) muscarinic receptor antagonists may represent a better treatment for overactive bladder syndrome, diminishing side effects. Cardiac side effects of non-selective antimuscarinics have been associated with activity at M(2) receptors as these receptors are mainly responsible for muscarinic receptor-dependent bradycardia. We have investigated a novel antimuscarinic, SVT-40776, highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 57 references

The effects of darifenacin and tolterodine on Heart Rate (HR) in patients with overactive bladder

  • B Olshansky, J Foote, M Arguinzoniz, K Lheritier, E Quebe-Fehling, M Steel
  • Neurourol Urodyn 25: A124.
  • 2006
Highly Influential
16 Excerpts

Carbamates derived from arylalkylamines

  • C Farrerons, J Catena, A Fernandez-Serrat, I Miquel, D Balsa, JI Bonilla
  • [WO
  • 2002
Highly Influential
2 Excerpts

Antimuscarinics and heart rate: results from a randomized, double-blind, placebo-controlled, 3 way crossover study in subjects over age 50

  • B Olshansky, U Ebinger, M Egermark, A Luthra, A Rekedac, J Brum
  • ICI 2008 July 5–8, Paris, Abst 32
  • 2008
2 Excerpts

Similar Papers

Loading similar papers…